NCI COMPASS-Comprehensive Oncologic Molecular Pathology and Sequencing Service

NCI COMPASS-综合肿瘤分子病理学和测序服务

• 批准号: 10703118
• 负责人: Liqiang Xi
• 金额: $ 839.07万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10703118
• 关键词: American; Biological Assay; CCR; Cancer Patient; Classification; Clinic; Clinical; Clinical Protocols; Clinical Research; Clinical Services; Complex; Continuing Education; Copy Number Polymorphism; Development; Diagnosis; Diagnostic; Diagnostic Services; Eligibility Determination; Genes; Genomics; Guidelines; Intramural Research Program; Laboratories; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Microsatellite Instability; Mission; Modernization; Molecular; Molecular Diagnostic Testing; Mutation; National Cancer Institute; National Human Genome Research Institute; National Institute of Allergy and Infectious Disease; National Institute of Arthritis, and Musculoskeletal, and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; Oncology; Pathogenicity; Pathologic; Pathologist; Pathology; Patients; Pediatric Oncology; Physicians; Play; Proteins; Protocols documentation; RNA; RNA Splicing; Reporting; Research; Role; Running; Sampling; Scientist; Services; Single Nucleotide Polymorphism; Solid Neoplasm; Specimen; Structure; Testing; Therapeutic; Training and Education; Tumor Markers; United States National Institutes of Health; Variant; base; cell free DNA; clinical center; clinically relevant; college; exome sequencing; gene panel; genome sequencing; insertion/deletion mutation; insight; molecular diagnostics; molecular oncology; molecular pathology; molecular targeted therapies; neuro-oncology; next generation; next generation sequencing; novel; precision oncology; prognostic; programs; rare cancer; screening; service programs; symposium; training opportunity; transcriptome sequencing; tumor; tumor behavior; whole genome

The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next generation sequencing to support clinical and research in CCR. In FY22 (July 2021 - June 2022), the NGS lab run 1376 TSO500, whole exome sequencing, and RNA exome sequencing tests. These results have provided support of precision pathological diagnosis and precision oncology for 75 clinical protocols from NCI and 9 protocol from NIAID, NIAMS, NIDDK, NHGRI including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. The program also developed and deployed whole exome sequencing, RNA exome sequencing assays into clinical service during FY22. The whole genome sequencing is in use for clinical and research especially for supporting CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. The cell-free circulating DNA NGS assay is still in development. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond particular patient or mutation.

分子诊断科目前是 NCI 内唯一获得 CLIA 和美国病理学院批准的临床实验室，可对 NIH 患者的病理材料进行分子肿瘤学检测。新建立的 COMPASS 计划旨在扩展下一代测序，以支持 CCR 的临床和研究。 2022 财年（2021 年 7 月至 2022 年 6 月），NGS 实验室运行了 1376 项 TSO500、全外显子组测序和 RNA 外显子组测序测试。这些结果为NCI的75个临床方案和NIAID、NIAMS、NIDDK、NHGRI的9个方案（包括CCR罕见肿瘤、肝癌和前列腺癌Moonshot项目）提供了精准病理诊断和精准肿瘤学支持。我们还在 CCR 壁内诊所的患者中筛选 NCI-MATCH 的目标。该计划还在 2022 财年开发了全外显子组测序、RNA 外显子组测序检测并将其部署到临床服务中。全基因组测序用于临床和研究，特别是支持 CCR 罕见肿瘤、肝癌和前列腺癌登月项目。无细胞循环 DNA NGS 检测仍在开发中。 COMPASS 计划通过举办每周 NGS 技术审查会议、每周分子病理学/神经肿瘤学会议和每周分子病理学/儿科肿瘤学会议来讨论分子发现、治疗以及特定患者或突变之外的问题，为病理学和肿瘤学团队，特别是下一代病理学家和医师科学家提供了培训或继续教育的绝佳机会。